Calling the move not only logical, but necessary, DeCode Genetics Inc. said it is buying MediChem Life Sciences Inc. in a stock swap worth about $83.6 million.

Calling the move not only logical, but necessary, DeCode Genetics Inc. said it is buying MediChem Life Sciences Inc. in a stock swap worth about $83.6 million.

Chiron Corp., its eyes firmly focused on the cancer therapeutic tezacitabine, is acquiring Matrix Pharmaceutical Inc. for $61 million in cash.

Chiron Corp., its eyes firmly focused on the cancer therapeutic tezacitabine, is acquiring Matrix Pharmaceutical Inc. for $61 million in cash.